Compare General Mills, Inc. (GIS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? General Mills, Inc. trades at $38.27 (market cap $20.24B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: General Mills, Inc. is far larger — about 11.2× Recursion Pharmaceuticals Inc's market cap, and General Mills, Inc. pays a 6.43% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| GIS | RXRX | |
|---|---|---|
Market Cap | $20.24B | $1.81B |
Sector | Consumer Staples | Health |
52-Week High | $51.11 | $6.79 |
52-Week Low | $32.17 | $2.84 |
Enterprise Value | $33.73B | $1.33B |
Dividend Yield | 6.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $37.97, up 1.89% today, showing a mixed technical picture with a bullish moving average signal but a neutral RSI. Fundamentally, the company reported a net loss in 2026, compressing margins, though it beat Q2 2026 EPS estimates. Recent news highlights strategic partnerships in regenerative agriculture and new product launches to drive growth amid challenging consumer demand.
The outlook is cautious; while the stock appears undervalued on a P/E basis and offers a dividend, significant risks include persistent margin pressure, high debt levels, and weak sales growth. Analyst consensus is predominantly Hold, reflecting uncertainty about the company's turnaround efforts in a competitive market.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
